Fundz

Kala Bio reported raising $2.25 Million in an initial SEC Form D filing, from an offering of $4.2 Million

PRIVATEFeb 13, 2026$2.3M of $4.2M raised

Amount Raised

$2.25 Million

$2.25 Million sold, per SEC Form D (first sale Jan 30, 2026)

Round Type

Venture

ArlingtonBiotechnology

Quick answer

Kala raised $2.25 Million in a funding round, dated January 30, 2026. Kala is based in Arlington, Massachusetts, United States.

How much did Kala raise?
Kala raised $2.25 Million in a funding round on January 30, 2026.
What does Kala do?
Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye.
Where is Kala based and how big is it?
Kala is based in Arlington, Massachusetts, United States.
Who are the decision-makers at Kala?
Fundz holds 1 contact at Kala, including the Chief Financial Officer . Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Kala that raised within 45 days of this round, from Fundz verified event records.

  • Longevity Health raised $200K on March 16, 2026.
  • Alto Neuroscience raised $120M (Post-IPO Equity) on March 16, 2026.
  • Betterhood raised $538K (Seed) on March 16, 2026.
  • Conexeu Sciences raised $45K on March 16, 2026.
  • Scinus Group raised $3.4M (Seed) on March 16, 2026.
  • Ovala, Inc. raised $3.3M (Seed) on March 16, 2026.

Who to call at Kala, and when

A new round usually means Kala is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Kala raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Kala, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Kala. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Kala

Location

Arlington, Massachusetts, United States

About

Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye. Kala’s biologics-based investigational therapies utilize Kala’s proprietary Mesenchymal Stem Cell Secretome (MSC-S) platform. Kala’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received orphan drug designation from the U.S. Food and Drug Administration. Kala is also targeting the potential development of KPI-012 for the treatment of Partial Limbal Stem Cell Deficiency and ocular manifestations of moderate-to-severe Sjögren's and plans to initiate preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Kala raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsMary R., Chief Financial Officer See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Kala's next move

See what Strategic adds

Kala raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.